N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
The present invention relates to compounds of formula I: in which p, q, Y 1 , Y 2 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 7 and R 8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
1. A method of treatment of lung cancer comprising administering a compound of formula I, or a pharmaceutically acceptable salt thereof, to a person in need of such treatment in an effective amount for the therapeutic treatment of lung cancer:
in which:
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
R 1 is −XR 1a ; wherein R 1a is selected from C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms or groups independently selected from N, C(O), O and S; wherein said aryl or heteroaryl of R 1a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, C 1-4 alkoxy, dimethyl-amino, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 , —C(O)NH 2 and —NHC(O)R 10 , wherein R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy; and X is selected from a bond, S(O) m , O, C(O), CR 10a R 10b , NR 11 ; wherein m is selected from 0, 1 and 2; each R 10a and R 10b is independently selected from halo and C 1-4 alkyl; and R 11 is selected from hydrogen and C 1-4 alkyl;
R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 3a and R 3b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 4a and R 4b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 5a and R 5b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino-carbonyl, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, —S(O) 1-2 R 6a , —C(S)R 6a , —C(O)NR 6a R 6b , —C(NH)NR 6a R 6b and —NR 6a C(O)R 6b ; wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain 1 to 3 heteroatoms or groups independently selected from N, C(O), O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, amino-methyl, methyl-amino and
isobutyryloxy.
2. The method of claim 1 wherein the compound is a compound of Formula Ia:
in which:
n is selected from 1, 2, 3 and 4;
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
each Y 4 is independently selected from N and CR 9 ;
R 6 is selected from hydrogen, halo, methyl and amino-carbonyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O, C(O) and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, halo, hydroxy, methyl, methoxy, amino-methyl, methyl-amino and isobutyryloxy;
R 9 is selected from halo, amino, hydroxy, N 3 , dimethyl-amino, C 1-4 alkyl, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 , —C(O)NH 2 and —NHC(O)R 10 ;
R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;
or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 5 member saturated or partially unsaturated ring that can optionally contain 1 to 2 heteroatoms or groups independently selected from N, O, C(O) and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, methyl-amino and isobutyryloxy; or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
5. The method of claim 2 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 6 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino; or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the compound, or the pharmaceutically acceptable salt thereof, is
7. The method of claim 2 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 4 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with a group selected from amino, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
8. The method of claim 7 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
9. The method of claim 2 in which p and q are both 0; or the pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the compound, or the pharmaceutically acceptable salt thereof, selected from:
11. The method of claim 1 , wherein the compound is a compound of formula II:
in which:
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
R 1 is —XR 1a ; wherein X is a bond and R 1a is selected from C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S; wherein said aryl or heteroaryl of R 1a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 and —NHC(O)R 10 , wherein R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;
R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 3a and R 3b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 4a and R 4b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 5a and R 5b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino-carbonyl, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl and amino-substituted C 1-4 alkyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, halo, hydroxy, amino-methyl and methyl-amino;
or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the compound is a compound of Formula IIa:
in which:
n is selected from 1, 2, 3 and 4;
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is selected from N;
Y 2 is selected from CR 6
Y 4 is selected from N and CR 9 ;
R 6 is selected from hydrogen, halo, methyl and amino-carbonyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with a group selected from amino, amino-methyl and methyl-amino;
R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, halo-substituted-C 1-4 alkyl, —C(O)OR 10 and —NHC(O)R 10 ;
R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;
or a pharmaceutically acceptable salt thereof.
13. The method of claim 12 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 5 member saturated or partially unsaturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino; or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
15. The method of claim 12 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 6 member saturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino; or a pharmaceutically acceptable salt thereof.
16. The method of claim 15 , wherein the compound, or the pharmaceutically acceptable salt thereof, is
17. The method of claim 12 in which R 7 and R 8 together with the carbon atom to which they are both attached form a 4 member saturated ring that can optionally contain a heteroatom selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino; or a pharmaceutically acceptable salt thereof.
18. The method of claim 17 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
19. The method of claim 12 in which p and q are both 0; or the pharmaceutically acceptable salt thereof.
20. The method of claim 19 , wherein the compound, or the pharmaceutically acceptable salt thereof, is
21. The method of claim 1 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
22. A method of treatment comprising administering:
or a pharmaceutically acceptable salt thereof, to a person in need of such treatment in an effective amount for the therapeutic treatment of lung cancer.